Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Conditions

Carcinoma, Renal Cell 23Kidney Neoplasms 10Neoplasms 8Carcinoma, Non-Small-Cell Lung 7Carcinoma 6Melanoma 4Lung Neoplasms 4Colorectal Neoplasms 4Neoplasm Metastasis 3Carcinoma, Hepatocellular 3Thyroid Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Kidney Diseases 2Clear-cell metastatic renal cell carcinoma 2Carcinoma, Adenoid Cystic 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uveal Melanoma 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Solid Tumors 1Skin Neoplasms 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Recurrence 1Prostatic Neoplasms 1Pheochromocytoma 1Paraganglioma 1

Interventions

pembrolizumab 3Axitinib 2regorafenib 1avelumab 1amivantamab 1Tretinoin 1Specimen Handling 1Radiation 1Pemetrexed 1Nelfinavir 1Magnetic Resonance Spectroscopy 1Glutamate Carboxypeptidase II 1GSK-3326595 1Etoposide 1Endoscopic Mucosal Resection 1Doxorubicin 1Cisplatin 1Bortezomib 14-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Carcinoma, Adenoid Cystic × Axitinib × Clear all
NCT03990571 2024-10-18

Axitinib and Avelumab in Treating Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma

M.D. Anderson Cancer Center

Phase 2 Completed
40 enrolled 13 charts

Carcinoma, Adenoid Cystic, Disease Progression

NCT01558661 2017-11-28

Axitinib (AG-013736) in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
33 enrolled 10 charts

Carcinoma, Adenoid Cystic, Neoplasm Metastasis, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡